Fennec Pharmaceuticals Inc (FRX)
Toronto Exchange · Canada · prices in CAD · close of 16 Oct 2026
Key indicators
| Last close | CAD 14.38 |
|---|---|
| 52-week range | 7.59 – 17.64 |
| Return, 1 month / 3 months | −2.3% / −3.5% |
| Return, 1 year / 3 years | +21.9% / +46.7% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 42 |
| Volatility (1 year) | 66.1% |
| Worst drawdown (1 year) | -36.1% |
| Average daily value traded | 0.01M CAD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Fennec Pharmaceuticals is a specialty pharmaceutical company focused on treatments that protect cancer patients from the side effects of chemotherapy. Its main product is an injectable medicine given to children receiving cisplatin-based chemotherapy to reduce the risk of hearing loss caused by the treatment. The company works with hospitals, oncology clinics and healthcare providers that care for paediatric cancer patients. Fennec is based in Research Triangle Park in North Carolina, in the United States.
The shares are listed on the Toronto Exchange in Canada under the code FRX, and the price on this page is in Canadian dollars (CAD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Fennec Pharmaceuticals Inc (FRX) trades on the Toronto Exchange in Canada. It last closed at CAD 14.38 on 16 October 2026.
Its price-based Market X-Ray is 50 out of 100 (a weak price profile), ranking 480 of 868 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 21.9% and over the last three months it fell 3.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Toronto Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 76 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 14.3% | ||
| From 52-week high | -18.4% | ||
| Momentum | 67 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -3.5% | ||
| 6-month return | 69.2% | ||
| 12-month return, skipping the last month | 24.7% | ||
| Stability (higher is calmer) | 32 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 66.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -36.1% | ||
| Liquidity | 5 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M CAD | ||
| Zero-volume days | 41.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −3.2% |
|---|---|
| 1 month | −2.3% |
| 3 months | −3.5% |
| 6 months | +69.2% |
| 1 year | +21.9% |
| 3 years | +46.7% |
| 5 years | – |
Signals
| 50-day / 200-day average | 15.80 / 12.58 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.36 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Toronto Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.